31 Mar 2023
Assets595.02
Total Income891.10
EBITDA135.03
Profit After Tax84.93
NET Worth408.52
Reserves and Surplus347.36
Total Borrowing2.33
Open 8th Dec 2025 · Close 10th Dec 2025 · Listing 15th Dec 2025
The shares listed at ₹1,470.00, a 38.42% move from the issue price. Corona Remedies is a Mainboard IPO with an issue size of ₹655.37 crore, proposed for listing on BSE, NSE. The offer opens on 8th Dec 2025 and closes on 10th Dec 2025. The issue structure includes an offer-for-sale component of ₹655.37 crore. The current listing schedule points to 15th Dec 2025.
| Investor | Lots | Shares | Amount |
|---|---|---|---|
| Minimum Bid | 1 | 14 | ₹14,868 |
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 27.50% |
| ROCE | 41.32% |
| Debt / Equity | 0.10% |
| RoNW | 24.65% |
| PAT Margin | 12.49% |
| EBITDA Margin | 20.55% |
| Price to Book Value | 10.71 |
| Expense | Amount |
|---|---|
| BRLMs fees and commissions (including underwriting commission, brokerage and selling commission) | ₹21.03 Cr |
| Fees payable to the Registrar to the Offer | ₹0.50 Cr |
| Selling commission/processing fee for SCSBs and Bankers to the Offer, fee payable to the Sponsor Bank(s) for Bids made by RIIs using UPI, brokerage and selling commission and bidding charges for the Members of the Syndicate, Registered Brokers, RTAs and CDPs | ₹3.07 Cr |
| Advertising and marketing expenses | ₹2.41 Cr |
| Others | — |
| Listing fees, SEBI filing fees, upload fees, BSE and NSE processing fees, book building software fees | ₹7.11 Cr |
| Other regulatory expenses | — |
| Printing and stationery expenses | ₹1.17 Cr |
| Fees payable to legal counsels | ₹8.81 Cr |
| Fees payable to other advisors to the Offer, including but not limited to Statutory Auditors, independent chartered accountant, practising company secretary, industry expert | ₹4.01 Cr |
| Miscellaneous | ₹3.85 Cr |